HRP20151263T1 - Natrijeva sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida - Google Patents

Natrijeva sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida Download PDF

Info

Publication number
HRP20151263T1
HRP20151263T1 HRP20151263TT HRP20151263T HRP20151263T1 HR P20151263 T1 HRP20151263 T1 HR P20151263T1 HR P20151263T T HRP20151263T T HR P20151263TT HR P20151263 T HRP20151263 T HR P20151263T HR P20151263 T1 HRP20151263 T1 HR P20151263T1
Authority
HR
Croatia
Prior art keywords
fluoro
hydroxy
sodium salt
pyrazinecarboxamide
crystal
Prior art date
Application number
HRP20151263TT
Other languages
English (en)
Inventor
Keiko Takakura
Namika Nakamatsu
Sakiko Takeshima
Sayuri Uehara
Original Assignee
Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co., Ltd. filed Critical Toyama Chemical Co., Ltd.
Publication of HRP20151263T1 publication Critical patent/HRP20151263T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)

Claims (5)

1. Kristal, naznačen time, da je to kristal natrijeve soli 6-fluor-3-hidroksi-2- pirazinkarboksamida ili njegovog hidrata.
2. Pripravak za injektiranje, naznačen time, da sadržava kristal natrijeve soli 6-fluor-3-hidroksi-2-pirazinkarboksamida ili njegovog hidrata.
3. Liofilizirani pripravak, naznačen time, da sadržava kristal natrijeve soli 6-fluor-3-hidroksi-2-pirazinkarboksamida.
4. Postupak za proizvodnju liofiliziranog pripravka koji sadržava kristal natrijeve soli 6-fluor-3-hidroksi-2-pirazinkarboksamida, naznačen time, da obuhvaća sljedeće korake: (1) hlađenje vodene otopine koja sadržava natrijevu sol 6-fluor-3-hidroksi-2-pirazinkarboksamida za proizvodnju zamrznutog proizvoda; (2) podizanje temperature zamrznutog proizvoda; (3) ponovno hlađenje zamrznutog proizvoda i (4) obavljanje liofilizacije.
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time, da je postizanje temperature zamrznutog proizvoda u rasponu od -15°C do -5°C u koraku podizanja temperature smrznutog proizvoda.
HRP20151263TT 2010-09-30 2015-11-24 Natrijeva sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida HRP20151263T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010221682 2010-09-30
EP11829253.1A EP2623498B1 (en) 2010-09-30 2011-09-29 Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
PCT/JP2011/072333 WO2012043700A1 (ja) 2010-09-30 2011-09-29 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミドのナトリウム塩

Publications (1)

Publication Number Publication Date
HRP20151263T1 true HRP20151263T1 (hr) 2015-12-18

Family

ID=45893139

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151263TT HRP20151263T1 (hr) 2010-09-30 2015-11-24 Natrijeva sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida

Country Status (20)

Country Link
US (3) US20130274472A1 (hr)
EP (1) EP2623498B1 (hr)
JP (1) JPWO2012043700A1 (hr)
CN (1) CN103209966B (hr)
CY (1) CY1117041T1 (hr)
DK (1) DK2623498T3 (hr)
ES (1) ES2554630T3 (hr)
HK (1) HK1183015A1 (hr)
HR (1) HRP20151263T1 (hr)
HU (1) HUE026872T2 (hr)
MY (1) MY161429A (hr)
PH (1) PH12015501649A1 (hr)
PL (1) PL2623498T3 (hr)
PT (1) PT2623498E (hr)
RS (1) RS54408B1 (hr)
SG (1) SG189161A1 (hr)
SI (1) SI2623498T1 (hr)
SM (1) SMT201600072B (hr)
TW (1) TWI552998B (hr)
WO (1) WO2012043700A1 (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
CA2794171C (en) 2010-03-24 2018-07-03 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
SI2623497T1 (sl) * 2010-09-30 2016-04-29 Toyama Chemical Co., Ltd. Megluminska sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida
MX360889B (es) * 2012-12-22 2018-11-20 Kbp Biosciences Co Ltd Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma.
US10765753B2 (en) * 2014-12-30 2020-09-08 Samyang Biopharmaceuticals Corporation Polymer nanoparticle freeze-dried product, and preparation method therefor
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
WO2018003946A1 (ja) * 2016-06-30 2018-01-04 富山化学工業株式会社 凍結乾燥製剤の製造方法
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
EP3733182A4 (en) * 2017-12-28 2021-09-01 FUJIFILM Toyama Chemical Co., Ltd. PROCESS FOR PREPARING A FREEZE-DRIED FORMULATION
MX2021005691A (es) 2018-11-19 2021-07-07 Jazz Pharmaceuticals Ireland Ltd Formulaciones de farmacos resistentes al alcohol.
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
CN111249229B (zh) * 2020-03-10 2023-05-02 北京阜康仁生物制药科技有限公司 一种稳定的法匹拉韦注射液及其制备方法
TR202017792A2 (tr) * 2020-11-06 2021-01-21 Aroma Ilac Sanayi Ltd Sti 6-floro-3-hidroksi-2-pirazinkarboksamid etken maddesi veya sodyum tuzunu içeren liyofilizasyon tekniğiyle üretilen yeni bir farmasötik kompozisyon
CN112546234B (zh) * 2020-12-11 2021-10-15 山东大学 一种法匹拉韦药用结合物及在制备抗病毒药物制剂中的应用
CN112574130B (zh) * 2020-12-11 2021-10-15 山东大学 一种法匹拉韦药物共晶及其制备方法和应用
WO2022131112A1 (ja) 2020-12-18 2022-06-23 富士フイルム富山化学株式会社 医薬組成物
CN116761591A (zh) 2020-12-18 2023-09-15 富士胶片富山化学株式会社 药物组合物
WO2023033683A1 (ru) * 2021-09-06 2023-03-09 Общество С Ограниченной Ответственностью "Промомед Рус" Противовирусная фармацевтическая композиция, содержащая фавипиравир и аминокислоту
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID25469A (id) 1998-01-07 2000-10-05 Meiji Seika Kaisha Komposisi sefalosporin amorf yang stabil secara kristalografi dan proses pembuatannya
WO2000010569A1 (fr) * 1998-08-20 2000-03-02 Toyama Chemical Co., Ltd. Derives heterocycliques azotes de carboxamide ou certains de leurs sels et antiviraux les contenant les deux
BRPI0108374B8 (pt) 2000-02-16 2021-05-25 Fujifilm Toyama Chemical Co Ltd derivado de pirazina ou um sal deste e composição farmacêutica
PL2123276T3 (pl) * 2007-02-16 2013-04-30 Toyama Chemical Co Ltd Kompozycja farmaceutyczna zawierająca pochodną pirazyny oraz sposób stosowania pochodnej pirazyny w kombinacji
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
JP2008231064A (ja) 2007-03-23 2008-10-02 Nippon Shokubai Co Ltd カルバゾイルアルキル(メタ)アクリレートの製造方法
CN104672153B (zh) 2007-09-27 2019-04-23 富士胶片富山化学株式会社 6-氟-3-羟基-2-氰基吡嗪的有机胺盐及其制备方法
SG174291A1 (en) 2009-03-13 2011-10-28 Toyama Chemical Co Ltd Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
SI2623497T1 (sl) 2010-09-30 2016-04-29 Toyama Chemical Co., Ltd. Megluminska sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida

Also Published As

Publication number Publication date
SMT201600072B (it) 2016-04-29
CN103209966A (zh) 2013-07-17
TWI552998B (zh) 2016-10-11
US20150038713A1 (en) 2015-02-05
US9096547B2 (en) 2015-08-04
HUE026872T2 (en) 2016-07-28
EP2623498A1 (en) 2013-08-07
PL2623498T3 (pl) 2016-05-31
EP2623498B1 (en) 2015-11-18
US20130274472A1 (en) 2013-10-17
CY1117041T1 (el) 2017-04-05
JPWO2012043700A1 (ja) 2014-02-24
TW201219375A (en) 2012-05-16
EP2623498A4 (en) 2014-03-26
PH12015501649B1 (en) 2015-10-05
MY161429A (en) 2017-04-14
SI2623498T1 (sl) 2016-03-31
ES2554630T3 (es) 2015-12-22
SG189161A1 (en) 2013-05-31
PT2623498E (pt) 2016-02-02
US20150266831A1 (en) 2015-09-24
WO2012043700A1 (ja) 2012-04-05
HK1183015A1 (en) 2013-12-13
DK2623498T3 (en) 2016-02-22
CN103209966B (zh) 2015-06-10
RS54408B1 (en) 2016-04-28
PH12015501649A1 (en) 2015-10-05

Similar Documents

Publication Publication Date Title
HRP20151263T1 (hr) Natrijeva sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida
HRP20160218T1 (hr) Megluminska sol 6-fluoro-3-hidroksi-2-pirazin karboksamida
IN2015KN00262A (hr)
WO2011056834A3 (en) Method to improve water solubility of rebaudioside d
MY190283A (en) Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
HRP20210699T1 (hr) Izmijenjeni kolagen
EA201591782A1 (ru) Наночастицы диоксида титана в форме рутила и их упорядоченные игольчатые агрегаты
RU2019138024A (ru) ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9c, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
PH12014000291A1 (en) Tobacco product wrapping material with controlled burning properties
CA2899024C (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
PH12015500794A1 (en) Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same
IN2014DN05767A (hr)
IN2014DN08783A (hr)
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
AU2018253648A1 (en) Process for producing low endotoxin chitosan
EA201591704A1 (ru) Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии
MY170779A (en) Method for the continuous production of an aliphatic or semi-aromatic polyamide oligomer
RU2011153245A (ru) Способ формирования защитного покрытия для хранения объектов водных биологических ресурсов с использованием модифицированных защитных покрытий
PH12016500261A1 (en) Nanoparticles and nanoparticle composition, and method for producing nanoparticles and nanoparticle composition
WO2015084693A3 (en) New process for preparing loratadine from a ketone intermediate
RU2016132562A (ru) Способ получения йогурта с наноструктурированным рибофлавином
JP2016019506A5 (hr)
RU2013135510A (ru) Способ получения карбоната натрия
RU2016129070A (ru) Способы получения биополимеров с заданной средней молекулярной массой
WO2015050199A3 (ja) 新規化合物、その製造方法及びその用途